Pathogenetic Mechanisms of Parkin in Parkinson's Disease
Lancet 364:722-724, Hattori,N. &Mizuno,Y., 2004
Interferon Beta-1a for Brain Tissue Loss in Patients at Presentation with Syndromes Suggestive of Multiple Sclerosis: A Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 364:1489-1496,1463, Filippi,M.,et al, 2004
Interferon beta-1b in Secondary Progressive MS
Neurol 63:1779-1787,1768, Kappos,L.,et al, 2004
Interferon beta-1b in Secondary Progressive MS
Neurol 63:1788-1795,1768, The North American Study Group on Interferon beta-, 2004
Clinical Manifestations of Cerebral Amyloid Angiopathy-Related Inflammation
Ann Neurol 55:250-256, Eng,J.A.,et al, 2004
The Topography of Metabolic Deficits in Posterior Cortical Atrophy (the Visual Variant of Alzheimers Disease) with FDG-PET
JNNP 74:1521-1529, Nestor,P.J.,et al, 2003
Genetic, Clinical, and Radiographic Delineation of Hallervorden-Spatz Syndrome
NEJM 348:33-40, Hayflick,S.J.,et al, 2003
Treatment of Sporadic Hemiplegic Migraine with Calcium-Channel Blocker Verapamil
Neurol 60:120-121, Yu,W. &Horowitz,S.H., 2003
Interferons in Relapsing Remitting Multiple Sclerosis: A Systematic Review
Lancet 361:545-552, Filippini,G.,et al, 2003
Neuroimaging and Early Diagnosis of Alzheimer Disease: A Look to the Future
Radiology 226:315-336, Petrella,J.R.,et al, 2003
Slowing Parkinson's Disease Progression
Neurol 60:381-389, Ahlskog,J.E., 2003
Initial Agonist Treatment of Parkinson Disease
Neurol 60:390-394, Albin,R.L. &Frey,K.A., 2003
[123I]b-CIT SPECT is a Useful Method for Monitoring Dopaminergic Degeneration in Early Stage Parkinson's Disease
JNNP 74:294-298,287, Winogrodzka,A.,et al, 2003
Neuronal Loss Is Greater in the Locus Coeruleus Than Nucleus Basalis and Substantia Nigra in Alzheimer and Parkinson Diseases
Arch Neurol 60:337-341, 320, Zarow,C.,et al, 2003
Alzheimer's Disease and Parkinson's Disease
NEJM 348:1356-1364, Nussbaum,R.L. &Ellis,C.E., 2003
Apoptosis and Caspases in Neurodegenerative Diseases
NEJM 348:1365-1375, Friedlander,R.M., 2003
Restless Legs Syndrome
NEJM 348:2103-2109, Earley,C.J., 2003
Validation of Diagnositc Magnetic Resonance Imaging Criteria for Multiple Sclerosis and Response to Interferon B1a
Ann Neurol 53:718-724, Barkhof,F.,et al, 2003
Mitochondrial Respiratory-Chain Diseases
NEJM 348:2656-2668, DiMauro,S. &Schon,E.A., 2003
Pathological Gambling Associated with Dopamine Agonist Therapy in Parkinson's
Neurol 61:422-423, Driver-Dunckley,E.,et al, 2003
Heart Valvular Disease in Patients with Parkinson's Disease Treated with High-Dose Pergolide
Neurol 61:859-861, VanCamp,G.,et al, 2003
Clinical Importance of Neutralising Antibodies Against Interferon Beta in Patients with Relapsing-Remitting Multiple Sclerosis
Lancet 362:1184-1191, Sorensen,P.S.,et al, 2003
MR Features of Diseases Involving Bilateral Middle Cerebellar Peduncles
AJNR 24:1946-1954, Okamoto,K.,et al, 2003
Prolactinoma
NEJM 349:2035-2041, Schlechte,J.A., 2003
Withdrawal of Long-Term Cabergoline Therapy for Tumoral and Nontumoral Hyperprolactinemia
NEJM 349:2023-2033, Colao,A.,et al, 2003
A Controlled Trial of Rotigotine Monotherapy in Early Parkinson's Disease
Arch Neurol 60:1721-1728, The Parkinson Study Group, 2003
Disease-Modifying Therapy in Multiple Sclerosis: Strategies for Optimizing Management
The Neurologist 8:227-236, Frohman,E.,et al, 2002
Excessive Daytime Sleepiness and Sudden-Onset Sleep in Parkinson Disease
JAMA 287:455-463,509, Hobson,D.E.,et al, 2002
An Open-Label Trial of Combination Therapy With Interferon B-1a and Oral Methotrexate in MS
Neurol 58:314-317, Calabresi,P.A.,et al, 2002
Disease Modifying Therapies in Multiple Sclerosis
Neurol 58:169-178, Goodin,D.S.,et al, 2002
Alopecia Induced by Dopamine Agonists
Neurol 58:829-830, Tabamo,R.E. &Di Rocco,A., 2002
Spinocerebellar Ataxia Type 10 is Rare in Populations Other Than Mexicans
Neurol 58:983-984, Matsuura,T.,et al, 2002
Multifocal Myoclonus Due to Verapamil Overdose
Neurol 58:984-985, Vadlamudi,L.&Wijdicks,E.F.M., 2002
Alzheimer Disease
JAMA 287:2335-2338, Cummings,J.L. &Cole,G., 2002
Cholinergic Vesicular Transporters in Progressive Supranuclesar Palsy
Neurol 58:1013-1018,997, Suzuki,M.,et al, 2002
Dopamine Transporter Brain Imaging to Assess the Effects of Pramipexole vs Levodopa on Parkinson Disease Progression
JAMA 287:1653-1661, Parkinson Study Group, 2002
Interferon Beta-1a for Early Multiple Sclerosis: CHAMPS Trial Subgroup Analyses
Ann Neurol 51:481-490, Beck,R.W.,et al, 2002
SUNCT Syndrome in Two Patient with Prolactinomas and Bromocriptine-Induced Attacks
Neurol 58:1698-1699, Massiou,H.,et al, 2002
Interferon Beta but not Glatiramer Acetate Therapy Aggravates Headaches in MS
Neurol 59:636-639, Pollmann,W.,et al, 2002
Benefit of Interferon B-1a on MSFC Progression in Secondary Progressive MS
Neurol 59:679-687, Cohen,J.A.,et al, 2002
Clinicopath Conf, Neuronal Ceroid Lipofuscinosis, Late-Onset Infantile Subtype
NEJM 347:672-680, Case 27-2002, 2002
A Randomized, Double-Blind, Dose-Comparison Study of Weekly Interferon B-1a in Relapsing MS
Neurol 59:1507-1517,1482, Clanet,M.,et al, 2002
Randomized, Comparative Study of Interferon B-1a Treatment Regimens in MS
Neurol 59:1496-1506,1482, Panitch,H.,et al, 2002
Recessive Ataxia With Ocular Apraxia
Arch Neurol 58:201-205,173, Barbot,C.,et al, 2001
SCA-12: Tremor with Cerebellar and Cortical Atrophy is Associated with a CAG Repeat Expansion
Neruol 56:299-303,287, O'Hearn,E.,et al, 2001
Headache and CNS White Matter Abnormalities Associated with Gluten Sensitivity
Neurol 56:385-388, Hadjivassiliou,M.,et al, 2001
Genetic Testing in Spinocerebellar Ataxias
Arch Neurol 58:191-195, Tan,E. &Ashizawa,T., 2001
Evaluation of CSf-tau and CSF-AB42 as Diagnostic Markers for Alzheimer Disease in Clinical Practice
Arch Neurol 58:373-379,349, Andreasen,N.,et al, 2001
Neurodegenerative Diseases and Prions
NEJM 344:1516-1526,1548, Prusiner,S.B., 2001
Effect of Early Interferon Treatment on Conversion to Definite Multiple Sclerosis: A Randomised Study
Lancet 357:1576-1582,1547, Comi,G.,et al, 2001